Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease

Arthritis Research and Therapy

Volumn 15, Issue 2, 2013, Pages

  Chen, Der Yuan ^a,b,c,d   Lin, Chi Chen ^d   Chen, Yi Ming ^a,b   Lan, Joung Liang ^e   Hung, Wei Ting ^a,b   Chen, Hsin Hua ^a,b   Lai, Kuo Lung ^a,b   Hsieh, Chia Wei ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MYD88 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN;

ADULT; ADULT ONSET STILL DISEASE; ARTICLE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MYELOID DENDRITIC CELL; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; BIOSYNTHESIS; BLOOD; DENDRITIC CELL; IMMUNOLOGY;

ADULT; BLOTTING, WESTERN; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; STILL'S DISEASE, ADULT-ONSET; TOLL-LIKE RECEPTOR 7;

EID: 84874437079     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4193     Document Type: Article

References (52)

1. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745. 10.1038/35047123, 11130078.
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
3. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835. 10.1038/nri1957, 17063184.
4. Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007, 19:11-23. 10.1016/j.smim.2006.12.005, 2709770, 17276080.
5. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002, 3:196-200. 10.1038/ni758, 11812998.
6. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, Ozaki Y, Tomizawa H, Akira S, Fukuhara S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subset. J Exp Med 2002, 195:1507-1512. 10.1084/jem.20020207, 2193542, 12045249.
7. Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. Type 1 interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res Ther 2009, 11:R112. 10.1186/ar2771, 2745794, 19624844.
8. Arthur M, Krieg Jörg V. Toll-like receptor 7, 8 and 9: linking innate immunity to autoimmunity. Immunological Reviews 2007, 220:251-269. 10.1111/j.1600-065X.2007.00572.x, 17979852.
9. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202:1131-1139. 10.1084/jem.20050914, 2213213, 16230478.
10. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007, 18:1721-1731. 10.1681/ASN.2006101162, 17460144.
11. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004, 4:499-511. 10.1038/nri1391, 15229469.
12. Sun D, Ding A. MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nat Immunol 2006, 7:375-381. 10.1038/ni1308, 16491077.
13. Bywaters EGL. Still's disease in the adults. Ann Rheum Dis 1971, 30:121-133. 10.1136/ard.30.2.121, 1005739, 5315135.
14. Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still's disease: Review of 228 cases from the literature. J Rheumatol 1987, 14:1139-1146.
15. Wouters JMGW, van der Veen J, van de Putte LBA, de Rooij DJRAM. Adult Still's disease and viral infection. Ann Rheum Dis 1988, 47:764-767. 10.1136/ard.47.9.764, 1003594, 3178317.
16. Chen DY, Chen YM, Lan JL, Tzang BS, Lin CC, Hsu TC. Significant association of past parvovirus B19 infection with cytopenia in both adult-onset Still's disease and systemic lupus erythematosus patients. Clin Chim Acta 2012, 413:855-860. 10.1016/j.cca.2012.01.027, 22309679.
17. Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, Suwa A, Hirakata M, Mimori T. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease: association with chronic articular disease. Rheumatology 2001, 40:1398-1404. 10.1093/rheumatology/40.12.1398, 11752512.
18. Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 2003, 30:2422-2427.
19. Chen DY, Hsieh TY, Hsieh CW, Lin FJ, Lan JL. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease. Arthritis Rheum 2007, 57:1530-1538. 10.1002/art.23088, 18050226.
20. Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006, 107:3229-3234. 10.1182/blood-2005-07-2650, 16368889.
21. Yu CF, Peng WM, Oldenburg J, Hoch J, Bieber T, Limmer A, Hartmann G, Barchet W, Eis-Hübinger AM, Novak N. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. J Immunol 2010, 184:1159-1167. 10.4049/jimmunol.0901706, 20026744.
22. Lombardi V, Van Overtvelt L, Horiot S, Moingeon P. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells. J Immunol 2009, 182:3372-3379. 10.4049/jimmunol.0801969, 19265114.
23. Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. Rheumatology (Oxford) 2010, 49:2305-2312.
24. Wong CK, Wong PTY, Tam LS, Li EK, Chen DP, and Lam CWK. Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2009, 159:11-22. 2802691, 19843090.
25. Komatsuda A, Wakui H, Iwamoto K, Ozawa M, Togashi M, Masai R, Maki N, Hatakeyama T, Sawada K. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008, 152:482-487. 10.1111/j.1365-2249.2008.03646.x, 2453201, 18373699.
26. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992, 19:424-430.
27. Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis. J Rheumatol 2010, 37:2369-2376. 10.3899/jrheum.100247, 20810496.
28. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
29. Bombaridier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35:630-640. 10.1002/art.1780350606, 1599520.
30. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
31. Chuang HC, Lan JL, Chen DY, Yang CY, Chen YM, Li JP, Huang CY, Liu PE, Wang X, Tan TH. GLK controls autoimmunity and NF-kB signaling by activating PKCθ in T cells. Nature Immunol 2011, 12:1113-1118.
32. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, Wagner TL, Tomai MA. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995, 58:365-372.
33. Shen N, Fu Q, Deng Y, Qian X, Zhao J, Kaufman KM, Wu YL, Yu CY, Tang Y, Chen JY, Yang W, Wong M, Kawasaki A, Tsuchiya N, Sumida T, Kawaguchi Y, Howe HS, Mok MY, Bang SY, Liu FL, Chang DM, Takasaki Y, Hashimoto H, Harley JB, Guthridge JM, Grossman JM, Cantor RM, Song YW, Bae SC, Chen S, Hahn BH, Lau YL, Tsao BP. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci USA 2010, 107:15838-15843. 10.1073/pnas.1001337107, 2936646, 20733074.
34. Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, Kusaoi M, Matsumoto I, Tohma S, Takasaki Y, Hashimoto H, Sumida T, Tsuchiya N. TLR7 single nucleotide polymorphisms in the 3' untranslated region and intron independently contribute to systemic lupus erythematosus in Japanese woman: a case-control association study. Arthritis Res Ther 2011, 13:R41. 10.1186/ar3277, 3132023, 21396113.
35. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428. 10.1016/j.immuni.2006.07.013, 16973389.
36. Kissner TL, Ruthel G, Cisney ED, Ulrich RG, Fernandez S, Saikh KU. MyD88-dependent proinflammatory cytokine response contributes to lethal toxicity of staphylococcal enterotoxin B in mice. Innate Immun 2010, 17:451-462.
37. Akira S, Takoda K, Kaisho I. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol 2001, 2:675-680.
38. Matsushima H, Yamada N, Matsue H, Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J Immunol 2004, 173:531-541.
39. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2481-2487. 10.1002/art.23613, 2621107, 18668568.
40. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336. 10.1146/annurev.immunol.23.021704.115843, 15771573.
41. Ronnblom L, Alm VG. Systemic lupus erythematosus and type 1 interferon system. Arthritis Res Ther 2003, 5:68-75.
42. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 10.1073/pnas.0337679100, 151388, 12604793.
43. Feng X, Wu H, Grossman JM, FitzGerald JD, Park GS, Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M, Taylor M, Brahn E, Hahn BH, Tsao BP. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:2951-2962. 10.1002/art.22044, 16947629.
44. Dalléra MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005, 64:1692-1697. 10.1136/ard.2004.033753, 1755300, 15843451.
45. Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J, Kellner ES, Nacionales D, Barker T, Kelly-Scumpia K, van Rooijen N, Kumar H, Kawai T, Satoh M, Akira S, Reeves WH. TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008, 205:2995-3006. 10.1084/jem.20080462, 2605237, 19047436.
46. Guiducci C, Tripodo C, Gonng M, Sangaletti S, Colombo MP, Coffman RL, Barrat FJ. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010, 207:2931-2942. 10.1084/jem.20101048, 3005224, 21115693.
47. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150. 10.1016/S1074-7613(00)80596-8, 9697844.
48. Lenert PS. Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus. Arthritis Res Ther 2006, 8:203. 10.1186/ar1888, 1526546, 16542467.
49. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582-3586. 10.1002/eji.200737815, 18034431.
50. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1785-1796. 10.1002/art.24557, 19479852.
51. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B. Lupus Interferon Skin Activity (LISA) Study Investigators.Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011, 70:1905-1913. 10.1136/ard.2010.144485, 21798883.
52. Hamilton-Williams EE, Lang A, Benke D, Davey GM, Wiesmuller KH, Kurts C. Cutting edge: TLR ligands are not sufficient to break cross-tolerance to self-antigens. J Immunol 2005, 174:1159-1163.